EP0000148A1 - Quinazolinone oxides and process for their preparation - Google Patents
Quinazolinone oxides and process for their preparation Download PDFInfo
- Publication number
- EP0000148A1 EP0000148A1 EP78100162A EP78100162A EP0000148A1 EP 0000148 A1 EP0000148 A1 EP 0000148A1 EP 78100162 A EP78100162 A EP 78100162A EP 78100162 A EP78100162 A EP 78100162A EP 0000148 A1 EP0000148 A1 EP 0000148A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- quinazolinone
- oxide
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
Definitions
- starting material (1) can be prepared by the process disclosed in U.S. Patent No. 3,398,139.
- the present invention relates to an improved process for making such N-methylaminobenzophenone anti-oximes, and novel intermediates used in the improved process.
- the present invention relates to a new process for the preparation of N-methylaminobenzophenone anti-oximes by alkylation, and subsequent hydrolysis, of the corresponding quinazoline oxides.
- the preparation of compounds of Formula III is accomplished in two interrelated stages.
- reaction products of Formula II (X, Y as defined) are then hydrolytically converted in the presence of base to the methylaminobenzophenone anti-oximes of Formula III (X, Y as defined).
- compounds of formula II which are preferred as intermediates are those where X is chlorine or bromine. More preferred compounds of formula II are those where X is chlorine or bromine and Y is hydrogen, chlorine or fluorine.
- Most preferred compounds are those where X is chlorine or bromine and Y is hydrogen or fluorine.
- 1-Methylquinazolinone oxides of Formula II can be prepared by treating a solution or mixture of a compound of Formula I, prepared as taught by Sulkowski and Childress, J. Org. Chem., 27 4424 (1962) or by the improved process disclosed by Middleton in copending U.S. Patent Application Serial Number filed simultaneously herewith (attorney's docket number CR-7794), and a suitable base with an alkylating agent in an inert organic solvent medium.
- the reaction is preferentially carried out at moderate temperatures of 50-75°, but this step can be effected at room temperature.or above.
- Suitable solvents include, but are not limited to, ethers such as tetrahydrofuran,.diethyl ether and glyme; amides of secondary amines such as N,N-dimethylformamide and N,N-dimethylacetamide.
- Representative bases useful in the generation of the alkali metal salt of a compound of Formula I include, but are not limited to, potassium carbonate, sodium hydride, sodium carbonate and sodium or potassium alkoxides such as sodium ethoxide or methoxide.
- the alkylated quinazolinone oxides can be isolated from the reaction mixture by conventional means, such as filtration of the insoluble product.
- the compound of Formula II can then be converted to the anti-oxime by heating with a base in an aqueous- alcoholic solvent.
- a base in an aqueous- alcoholic solvent.
- the reaction is conveniently carried out at the reflux temperature of the solvent.
- Useful alcoholic solvents include, but are not limited to, ethanol, methanol, propanol, isopropanol, butanol, 2-methoxyethanol, ethylene glycol and propylene glycol.
- suitable bases are alkali metal (such as sodium and potassium) hydroxides, carbonates and bicarbonates.
- the alkylaminobenzophenone anti-oximes obtained can be purified by evaporation of the reaction solvent and recrystallization of the solid residue.
- the yellow solid was dissolved in 350 ml of hot 1-chlorobutane. This hot viscous solution was filtered through a coarse fritted glass funnel. The filter and empty flask were thoroughly rinsed with exactly 150 ml of 1-chlorobutane and added to the filtrate. A total of only 500 ml of 1-chlorobutane was used. On addition of 2,000 ml of hexane to the chlorobutane solution, the desired product precipitated out.
- the anti-5-chloro-2-(N-methylamino)benzophenone oxime was obtained either in 88% yield (crystalline form "a", m.p. 90-91°) or 80% yield (crystalline form "b", m.p.
- the anti-oxime obtained exists in two different crystalline modifications. Their solid infrared spectra differ, as do color and solubility. The least soluble crystalline form, "a” precipitates out immediately on addition of hexane to the 1-chlorobutane solution. It is quite yellow, fluffy and obtained in good yield. The crystalline form "b” is more soluble and is obtained when hexane addition does not cause rapid precipitation, but rather a slow crystallization which requires thorough cooling. The material is pale yellow and crystalline.
- Table I shows additional 1-methylquinazolinone 3-oxides that can be prepared by the processes disclosed and illustrated above using the appropriate quinazolinone 3-oxide and a suitable methylating agent.
- Table II shows additional methylaminobenzophenone anti-oximes that can be prepared by the processes disclosed and illustrated above using the appropriate 1-methylquinazolinone 3-oxide and a suitable base.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Quinazolinone oxides of formula
<CHEM>
where X:Cl, Br, NO2, CF3,
Y:H, Br, Cl, F
process for their preparation and their use as intermediates in the preparation of 3-fluorobenzodiazepines which are useful as tranquilizers, muscle relaxants and sedatives.
Description
-
- X is Cl, Br, N02, or CF3;
- Y is H, Cl, Br or F;
- D is H, hydrocarbyl of 1-4 carbons, -CH2CF3, -CONHR, -CH2CH2NR2, or -CH2CH2NR2·A, where R is alkyl of 1-4 carbons and A is a pharmaceutically suitable acid;
- B is O; or
- B and D together is =N-N=C(R')-where R' is H or C1-C4 alkyl,
- In addition, copending U.S. Patent Application Serial No. , filed simultaneously with the present application by William Joseph Middleton (attorney's docket number CR-7796) discloses an improved process for preparing such 3-fluorobenzodiazepines, which improved process can be summarized schematically by the following equations:
- X is Cl, Br, NO2 or CF3;
- Y is H, Cl, Br or F; and
- Z1 and Z2 are Cl or Br.
- Middleton also discloses that starting material (1) can be prepared by the process disclosed in U.S. Patent No. 3,398,139.
- The present invention relates to an improved process for making such N-methylaminobenzophenone anti-oximes, and novel intermediates used in the improved process.
-
- The preparation of compounds of Formula III is accomplished in two interrelated stages. The first stage involves the alkali metal salt of quinazolinone 3-oxides of Formula I (X = Cl, Br, CF3 or N02; Y = H, Br, Cl or F) with alkylating agents of Formula CH3Z; (Z = I, Cl, Br, CF3SO2O-, FSO2O-, CCl3SO2O- or CH3OSO2O-) to give 1-methylquinazoline 3-oxides of Formula II (X and Y as defined).
- The reaction products of Formula II (X, Y as defined) are then hydrolytically converted in the presence of base to the methylaminobenzophenone anti-oximes of Formula III (X, Y as defined).
- Compounds from within the scope of U.S. Patent Application Serial Number 687,318 which are preferred for their activity are those shown in formula IV where, independently:
- B = 0;
- X = Cl;
- D = H;
- D = C1-C3 alkyl;
- X = Cl and D = H;
- X = Cl and D = C1-C3 alkyl.
- More preferred are those compounds where:
- X = Cl or Br;
- Y = H, Cl, or F;
- D = H, -CH3, or -C2H5; and
- B = O.
- Most preferred are those compounds where:
- X = Cl or Br;
- Y = H or F;
- D = CH3; and
- B = O.
- Necessarily, then, compounds of formula II which are preferred as intermediates are those where X is chlorine or bromine. More preferred compounds of formula II are those where X is chlorine or bromine and Y is hydrogen, chlorine or fluorine.
- Most preferred compounds are those where X is chlorine or bromine and Y is hydrogen or fluorine.
- Specifically preferred are the following compounds:
- 6-chloro-l-methyl-4-phenyl-2(lH)quinazolinone 3-oxide;
- 6-bromo-l-methyl-4-phenyl-2(lH)quinazolinone 3-oxide.
- 1-Methylquinazolinone oxides of Formula II can be prepared by treating a solution or mixture of a compound of Formula I, prepared as taught by Sulkowski and Childress, J. Org. Chem., 27 4424 (1962) or by the improved process disclosed by Middleton in copending U.S. Patent Application Serial Number filed simultaneously herewith (attorney's docket number CR-7794), and a suitable base with an alkylating agent in an inert organic solvent medium. The reaction is preferentially carried out at moderate temperatures of 50-75°, but this step can be effected at room temperature.or above. Suitable solvents include, but are not limited to, ethers such as tetrahydrofuran,.diethyl ether and glyme; amides of secondary amines such as N,N-dimethylformamide and N,N-dimethylacetamide. Representative bases useful in the generation of the alkali metal salt of a compound of Formula I include, but are not limited to, potassium carbonate, sodium hydride, sodium carbonate and sodium or potassium alkoxides such as sodium ethoxide or methoxide.
- The alkylated quinazolinone oxides can be isolated from the reaction mixture by conventional means, such as filtration of the insoluble product.
- The compound of Formula II can then be converted to the anti-oxime by heating with a base in an aqueous- alcoholic solvent. The reaction is conveniently carried out at the reflux temperature of the solvent. Useful alcoholic solvents include, but are not limited to, ethanol, methanol, propanol, isopropanol, butanol, 2-methoxyethanol, ethylene glycol and propylene glycol. Examples of suitable bases are alkali metal (such as sodium and potassium) hydroxides, carbonates and bicarbonates.
- The alkylaminobenzophenone anti-oximes obtained can be purified by evaporation of the reaction solvent and recrystallization of the solid residue.
- The following examples further illustrate the improved process of the present invention and the synthesis of the novel compounds of formula II. Parts are by weight and temperatures are in degrees centigrade unless otherwise stated.
-
- A mixture of 40 g (0.146 mole) of 6-chloro-4-phenyl-2(lH)quinazolinone 3-oxide in 1000 ml of N,N-dimethylformamide was treated with sodium hydride (7.7 g 50% in oil, 0.16 mole) and heated to 60°. The mixture was cooled to 10° and 30 g (0.211 mole) of methyl iodide was added during 5 minutes. The reaction mixture was stirred at room temperature for two hours and the solid collected by filtration, washed and dried. The crude solid (30.2 g) was recrystallized from N,N-dimethylformamide to give, in two. crops, 24.3 g (58%) of yellow plates identified as 6-chloro-l-methyl-4-phenyl-2(lH)quinazolinorie 3-oxide: m.p. 289-291°,
- Anal. Calc'd. for C15H11ClN2O2: C, 62.84; H, 3.87; N, 9.77
- Found: C, 63.01; H, 3.84; N, 9.79
-
- Anal. Calc'd. for C14N13N2OCl: C, 64.50; H, 5.03; N, 10.74 Found: C, 64.75; H, 4.92; N, 10.69
-
- A mixture of 125 g (0.458 mole) of 6-chloro-4-phenyl-2(lH)quinazolinone 3-oxide, 3,250 ml of N,N-dimethylformamide and 75 of powdered anhydrous potassium carbonate was heated to 50%. After heating for approximately 30 minutes at this temperature, an increased solubility of the suspended solid due to formation of the potassium salt of I was observed. At this point, 150 g (65.8 ml) of methyl iodide was added dropwise at a fast rate. The reaction with the methyl iodide was somewhat exothermic and caused the pot temperature to rise to 58°. Stirring at 50-55° was continued for 1 hour. The contents of the flask were cooled and filtered and the solid obtained was thoroughly washed with water. The product, 6-chloro- l-methyl-4-phenyl-2(lH)quinazolinone 3-oxide was obtained in 80% yield (103.2 g), m.p. 253.5-254°.
-
- The 6-chloro-1-methyl-4-phenyl-2(1H)quinazolinone 3-oxide, 286.7 g (1 mole) was mixed with 2,000 ml of ethanol and 200 ml of a 1N NaOH solution was added. The mixture was refluxed for 2 hours, cooled and filtered to remove a small amount of sodium bicarbonate (~14 g). This ethanol solution was evaporated to dryness under reduced pressure (bath temp. not to exceed~40°) to give a solid. Evacuation with a pump removed the last traces of ethanol.
- The yellow solid was dissolved in 350 ml of hot 1-chlorobutane. This hot viscous solution was filtered through a coarse fritted glass funnel. The filter and empty flask were thoroughly rinsed with exactly 150 ml of 1-chlorobutane and added to the filtrate. A total of only 500 ml of 1-chlorobutane was used. On addition of 2,000 ml of hexane to the chlorobutane solution, the desired product precipitated out. The anti-5-chloro-2-(N-methylamino)benzophenone oxime was obtained either in 88% yield (crystalline form "a", m.p. 90-91°) or 80% yield (crystalline form "b", m.p. 86-88°) [209-230 g]. The anti-oxime obtained exists in two different crystalline modifications. Their solid infrared spectra differ, as do color and solubility. The least soluble crystalline form, "a" precipitates out immediately on addition of hexane to the 1-chlorobutane solution. It is quite yellow, fluffy and obtained in good yield. The crystalline form "b" is more soluble and is obtained when hexane addition does not cause rapid precipitation, but rather a slow crystallization which requires thorough cooling. The material is pale yellow and crystalline.
-
- A mixture of 7.15 g (0.025 mole) of 6-chloro-l-methyl-4-phenyl-2(lH)quinazolinone 3-oxide, 100 ml of ethanol, 15 ml of water and 0.325 g (0.012 mole) of sodium carbonate was refluxed for 2 hours. The mixture was added to an equal volume of ice water and extracted with methylene chloride. The dried (MgS04) organic extracts were evaporated to dryness and the residue dissolved in a minimum amount of 1-chlorobutane. Hexane was added, and the solution was cooled to give 3.44 g of 5-chloro-2-methylaminobenzophenone anti-oxime (m.p. 85-86°).
-
- To a suspension of 5 g (0.018 mole) of 6-chloro-4-phenyl-2-(lH)quinazolinone 3-oxide and 125 ml of N,N-dimethylformamide was added, at room temperature, 0.96 g. of sodium hydride (50% in oil). The temperature rose to 30° and the stirring was continued for approximately 30 minutes to effect salt formation. To this mixture was added, dropwise, 6 g (0.042 mole) of methyl iodide. Stirring was continued for approximately 2 hours and the solid was collected by filtration, washed with water and with 10 ml of 1N HC1 to give 3.98 g (78%) of product identified as 6-chloro-l-methyl-4-phenyl-2(lH)-quinazoline 3-oxide: m.p. 253-254°. 1H nmr (CF3CO2H) 6 3.12 ppm (s, 3H); 6 6.5-7.3 (m, 8H, aromatic).
-
- A.mixture of 17 g (0.053 mole) of 6-bromo-4-phenyl-2(lH)quinazolinone 3-oxide, 400 ml of N,N-dimethylformamide and 9.1 g (0.065 mole) of powdered anhydrous potassium carbonate was heated to 50°. The contents of the flask were stirred at 50° for 30 minutes, at which time 8 ml (18 g) of methyl iodide was added dropwise at a fast rate. Stirring at 50-55° was continued for one hour. The solid portion of the cooled mixture was collected by filtration and washed with water to give 13.07 g (74%) of yellow crystalls identified as 6-bromo-l-methyl-4-phenyl-2(lH)quinazolinone 3-oxide: m.p. 279-279.5°; 1H nmr (CF3C02H) δ 3.05 (s, 3H), δ 6.5-7.5 ppm (m, 8H).
- Anal. Calc'd. for C15H11BrN2O2: C, 54.40; H, 3.35; N, .8.46 Found: C, 54.24; H, 3.39; N, 8.79
-
-
and the use of such compounds as tranquilizers, muscle relaxants and sedatives in mammals. In addition, Bingham and Middleton disclose a process for making such compounds by reaction of the corresponding 3-hydroxybenzodiazepine with a dialkylaminosulfur trifluoride as follows:
or taken together are -(CH2)4- or -(CH2)5.
Claims (9)
2. A compound of claim 1 where X is chlorine or bromine.
3. A compound of claim 1 where Y is hydrogen, chlorine or fluorine.
4. A compound of claim 2 where Y is hydrogen, chlorine or fluorine.
5. A compound of claim 2 where Y is hydrogen or fluorine.
6. The compound of claim 1 where X is chlorine and Y is hydrogen.
9. A process for preparing a compound of the formula:
where
X is Cl, Br, NO2 or CF3; and
Y is H, Cl, Br or F;
which comprises the following steps in sequence:
which comprises the following steps in sequence:
(a) treating the alkali metal salt of a compound of the formula
with an alkylating agent of the formula CH3Z, to produce a compound of the formula:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/807,074 US4160092A (en) | 1977-06-16 | 1977-06-16 | Quinazolinone oxides and their use as intermediates for pharmaceutical agents |
US807074 | 2007-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0000148A1 true EP0000148A1 (en) | 1979-01-10 |
Family
ID=25195499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100162A Withdrawn EP0000148A1 (en) | 1977-06-16 | 1978-06-15 | Quinazolinone oxides and process for their preparation |
Country Status (17)
Country | Link |
---|---|
US (1) | US4160092A (en) |
EP (1) | EP0000148A1 (en) |
JP (1) | JPS545989A (en) |
AR (1) | AR218668A1 (en) |
AT (1) | AT359057B (en) |
AU (1) | AU3713878A (en) |
DK (1) | DK176478A (en) |
ES (1) | ES470829A1 (en) |
FI (1) | FI781929A (en) |
GR (1) | GR64974B (en) |
IL (1) | IL54922A0 (en) |
IT (1) | IT1098333B (en) |
NO (1) | NO782086L (en) |
NZ (1) | NZ187582A (en) |
PT (1) | PT68173A (en) |
SU (1) | SU731893A3 (en) |
ZA (1) | ZA783440B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5684735U (en) * | 1979-12-03 | 1981-07-08 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754246A (en) * | 1970-07-31 | 1970-12-31 | Sumitomo Chemical Co | Novel quinazoline derivs prepn |
CH573412A5 (en) * | 1971-08-17 | 1976-03-15 | Sumitomo Chemical Co | 1-substd 4-aryl-2(1h) quinazolinones - anti-inflammatories, analgesics, uricosurics, andantivirals |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BG16042A3 (en) * | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
-
1977
- 1977-06-16 US US05/807,074 patent/US4160092A/en not_active Expired - Lifetime
-
1978
- 1978-04-24 DK DK176478A patent/DK176478A/en not_active Application Discontinuation
- 1978-06-09 AR AR272533A patent/AR218668A1/en active
- 1978-06-15 ES ES470829A patent/ES470829A1/en not_active Expired
- 1978-06-15 NZ NZ187582A patent/NZ187582A/en unknown
- 1978-06-15 ZA ZA00783440A patent/ZA783440B/en unknown
- 1978-06-15 PT PT68173A patent/PT68173A/en unknown
- 1978-06-15 AU AU37138/78A patent/AU3713878A/en active Pending
- 1978-06-15 EP EP78100162A patent/EP0000148A1/en not_active Withdrawn
- 1978-06-15 IT IT24614/78A patent/IT1098333B/en active
- 1978-06-15 NO NO782086A patent/NO782086L/en unknown
- 1978-06-15 IL IL7854922A patent/IL54922A0/en unknown
- 1978-06-15 AT AT436778A patent/AT359057B/en not_active IP Right Cessation
- 1978-06-16 SU SU782626798A patent/SU731893A3/en active
- 1978-06-16 GR GR56540A patent/GR64974B/en unknown
- 1978-06-16 FI FI781929A patent/FI781929A/en not_active Application Discontinuation
- 1978-06-16 JP JP7368078A patent/JPS545989A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754246A (en) * | 1970-07-31 | 1970-12-31 | Sumitomo Chemical Co | Novel quinazoline derivs prepn |
CH573412A5 (en) * | 1971-08-17 | 1976-03-15 | Sumitomo Chemical Co | 1-substd 4-aryl-2(1h) quinazolinones - anti-inflammatories, analgesics, uricosurics, andantivirals |
Also Published As
Publication number | Publication date |
---|---|
DK176478A (en) | 1978-12-17 |
NZ187582A (en) | 1980-11-28 |
AR218668A1 (en) | 1980-06-30 |
AU3713878A (en) | 1979-12-20 |
AT359057B (en) | 1980-10-27 |
JPS545989A (en) | 1979-01-17 |
ES470829A1 (en) | 1979-10-01 |
ATA436778A (en) | 1980-03-15 |
SU731893A3 (en) | 1980-04-30 |
IT7824614A0 (en) | 1978-06-15 |
ZA783440B (en) | 1979-06-27 |
GR64974B (en) | 1980-06-11 |
PT68173A (en) | 1978-07-01 |
IT1098333B (en) | 1985-09-07 |
NO782086L (en) | 1978-12-19 |
IL54922A0 (en) | 1978-08-31 |
US4160092A (en) | 1979-07-03 |
FI781929A (en) | 1978-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103342633B (en) | For the preparation of the method for benzofuran compounds | |
BG62554B1 (en) | METHOD FOR SILDENAFIL PREPARATION 16 claims METHOD FOR SILDENAFIL PREPARATION | |
EP2349964B1 (en) | Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds | |
DE60025803T2 (en) | PREPARATION OF SULPHONAMIDES | |
US6187926B1 (en) | Process for producing quinolone derivatives | |
SG172267A1 (en) | Process for the preparation of anagrelide and analogues | |
KR20180116371A (en) | Process for producing 4-alkoxy-3-hydroxypicolic acid | |
JPH0699396B2 (en) | Novel oxazolopyridine derivative | |
EP0000148A1 (en) | Quinazolinone oxides and process for their preparation | |
US4194049A (en) | 2-[[2-Methyl-1-[2-benzoyl(or benzyl)phenyl]-1H-imidazol-5-yl]methyl]-1H-isoindole-1,3(2H)-diones | |
LEONARD et al. | SOME NOVEL REACTIONS OF 4-QUINAZOLONE1, 2 | |
EP0273321B1 (en) | 7-bromo-beta-carboline compound and method for producing same | |
DE69012881T2 (en) | Preparation of N- (3 - (((aryl) amino) sulfonyl) -1H-1,2,4-triazol-5-yl) amines. | |
Heyman | Preparation of isatoates from isatoic anhydride | |
HU202813B (en) | Process for producing dialkyl-acetals containing keto-groups | |
WO2003053900A1 (en) | Method for producing deoxybenzoins | |
PL75399B3 (en) | Certain 2,4-diamino-5-benzyl-6-alkylthiopyrimidines[us3822264a] | |
US3262975A (en) | 1-chloro-3, 4-dihydro 2-naphthaldehyde oxime and ethers thereof | |
US4313950A (en) | Antireproductive tricyclic ortho-fused nitrogen containing compounds | |
DK156391B (en) | ANALOGY PROCEDURE FOR PREPARING 3-AMINOPYR ROLLER DERIVATIVES | |
US3590044A (en) | Process for the preparation of 1,2,3,4-tetrahydroisoquinoline-2-carboxamidines | |
Straub | Regioselective metalation of ortho-aminopicolines using the pivaloyl group as a directing group: synthesis of naphthyridines | |
JP3005080B2 (en) | Method for producing cyclopenta [d] pyrimidin-4-ones | |
CN117886725A (en) | Preparation process of apremilast intermediate | |
KR810001891B1 (en) | Process for preparing pheylethylamines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE Kind code of ref document: A1 Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19810403 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BINGHAM, ELENA MARIA Inventor name: ELLIOT, ARTHUR JOHN |